Helix BioPharma (TSE:HBP)
TSX:HBP
Top Page
Helix BioPharma
(TSX:HBP)
Select Model
Select Model
Rating:44Neutral
Price Target:
C$2.00
▼(-16.67% Downside)
Action:ReiteratedDate:03/18/26
The score is primarily held back by weak financial performance (no revenue, ongoing losses, and sustained cash burn), only partly offset by low leverage and recent equity strength. Technical signals are mildly bearish/neutral, and valuation support is limited due to negative earnings and no dividend.
Positive Factors
Low leverage / solid equity base
Very low leverage (TTM debt/equity ~0.02) and roughly $15.4M equity reduce near-term solvency risk and interest burden, giving management flexibility to fund R&D. This balance sheet cushion is a durable advantage versus highly leveraged peers.
Negative Factors
No revenue / persistent operating losses
The company has no commercial revenue and posts recurring operating losses (TTM net loss ~$4.2M). Absent product sales, operations rely on financing or deals; persistent unprofitability constrains long-term self-sufficiency and increases execution risk across clinical programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / solid equity base
Very low leverage (TTM debt/equity ~0.02) and roughly $15.4M equity reduce near-term solvency risk and interest burden, giving management flexibility to fund R&D. This balance sheet cushion is a durable advantage versus highly leveraged peers.
Read all positive factors
Helix BioPharma (HBP) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$129.84M
Dividend YieldN/A
Average Volume (3M)13.00K
Price to Earnings (P/E)―
Beta (1Y)1.98
Revenue GrowthN/A
EPS Growth59.00%
CountryCA
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding76,378,100
10 Day Avg. Volume29,165
30 Day Avg. Volume13,000
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)3.83
Price to Sales (P/S)0.00
P/FCF Ratio-15.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Helix BioPharma Business Overview & Revenue Model
Company Description
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has ...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Helix BioPharma’s ability to generate recurring revenue from product sales depends on successfully advancing drug candidates through clinical development and obtaining regulatory approval; publicly av...
Helix BioPharma Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Jul 2025 | Jul 2024 | Jul 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -4.00K | -10.00K | -14.00K | -13.00K | -12.00K | -173.00K |
| EBITDA | -3.94M | -5.21M | -9.38M | -6.31M | -6.03M | -9.46M |
| Net Income | -4.20M | -5.21M | -9.26M | -6.29M | -6.08M | -7.91M |
Balance Sheet | ||||||
| Total Assets | 18.52M | 18.80M | 1.49M | 1.03M | 3.73M | 4.07M |
| Cash, Cash Equivalents and Short-Term Investments | 31.00K | 65.00K | 1.08M | 808.00K | 3.25M | 3.56M |
| Total Debt | 359.00K | 335.00K | 0.00 | 0.00 | 2.47M | 3.61M |
| Total Liabilities | 3.16M | 3.22M | 1.58M | 1.87M | 3.41M | 5.46M |
| Stockholders Equity | 15.36M | 15.59M | -90.00K | -844.00K | 319.00K | -1.39M |
Cash Flow | ||||||
| Free Cash Flow | -3.71M | -3.83M | -5.23M | -5.54M | -6.51M | -9.30M |
| Operating Cash Flow | -3.71M | -3.83M | -5.22M | -5.53M | -6.51M | -9.30M |
| Investing Cash Flow | 0.00 | 17.00K | -14.00K | -5.00K | 0.00 | 2.02M |
| Financing Cash Flow | 1.74M | 2.80M | 5.51M | 3.09M | 6.21M | 6.56M |
Helix BioPharma Technical Analysis
Negative
2.40
Price Trends
1.91
Negative
2.09
Negative
1.84
Negative
Market Momentum
-0.05
Negative
42.06
Neutral
57.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:HBP, the sentiment is Negative. The current price of 2.4 is above the 20-day moving average (MA) of 1.82, above the 50-day MA of 1.91, and above the 200-day MA of 1.84, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 42.06 is Neutral, neither overbought nor oversold. The STOCH value of 57.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:HBP.
Helix BioPharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | C$129.84M | -55.85 | -66.34% | ― | ― | 59.00% | |
44 Neutral | C$171.86M | -4.57 | -51.42% | ― | ― | 27.53% | |
42 Neutral | C$42.61M | -4.40 | -103.51% | ― | ― | 54.74% | |
39 Underperform | C$40.16M | -12.93 | 72.34% | ― | ― | 10.49% |
* Healthcare Sector Average
TSE:HBP
Helix BioPharma
1.70
0.91
115.19%
TSE:MSCL
Satellos Bioscience
8.25
0.45
5.78%
TSE:ARCH
Arch Biopartners
0.60
-0.96
-61.54%
TSE:MDNA
Medicenna Therapeutics Corp
0.62
-0.31
-33.33%
TSE:METX
ME Therapeutics Holdings, Inc.
2.50
-7.50
-75.00%
TSE:ONCO
Onco-Innovations Ltd.
1.47
-0.10
-6.37%
Helix BioPharma Corporate Events
Business Operations and StrategyProduct-Related Announcements
Helix BioPharma Showcases CEACAM6-Targeted ADC Advances at World ADC London
Positive
Feb 24, 2026
Helix BioPharma unveiled new data on its CEACAM6-directed antibody-drug conjugate program at the 16th Annual World ADC London conference, highlighting a proprietary VHH-based nanobody with tumor-selective binding. The company said the data support...
Business Operations and Strategy
Helix BioPharma Extends LEUMUNA Option with metaShape in Metabolic Disease Push
Positive
Feb 5, 2026
Helix BioPharma has extended metaShape Pharma’s exclusive research and option agreement for LEUMUNA in adipose tissue-related and metabolic diseases through December 31, 2028, preserving Helix’s rights to a potential high-value metabol...
Business Operations and StrategyExecutive/Board ChangesShareholder MeetingsStock Split
Helix BioPharma Shareholders Back Board, Auditor and Share Consolidation Plan
Positive
Jan 31, 2026
Helix BioPharma Corp. reported that shareholders overwhelmingly approved all matters at its latest annual general and special meeting, with more than 81% of outstanding shares voted and all four director nominees re-elected by near-unanimous suppo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.